Refine by
Solid Tumor Articles & Analysis
240 news found
"Think of vaccines as a training camp for the immune system," says a scientist at Creative Biolabs, a US-based biotechnology company providing services to support early stage vaccine research, "which don't just fend off viruses and teach the body to recognize and eliminate tumor cells." The COVID-19 pandemic reminded the world of just how fast vaccine science can move from ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
Liquid biopsy testing offers a complementary alternative to solid tumor testing, which is not always feasible due to insufficient tissue, low quality tissue, or the invasiveness of the procedure. The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays. ADCs are an expanding class of therapies designed to target and kill tumor cells while sparing healthy cells. These very targeted therapies are available to patients ...
ByTempus
Tempus introduced its first MRD test, xM MRD, for research use in January 2024. The rapid, tumor-naïve plasma based test is designed to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage colorectal cancer (CRC) after curative intent surgery. xM was developed using the company’s multimodal database and advanced machine ...
ByTempus
The first candidate under development by Oncovita, MVdeltaC, is an immunotherapeutic treatment for solid tumors and has demonstrated remarkable immunogenic oncolysis properties in human or syngeneic tumor models, e.g. mesothelioma, bladder, neuroblastoma, etc. ...
ByOncoVITA
An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple immune-suppressive mechanisms in the tumor microenvironment. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is ...
ByBayer AG
The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors. The antibody was transferred to Aulos Bioscience, a Biolojic spinoff that is now conducting clinical trials in Australia and is currently ...
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with ...
” At data cutoff (July 16, 2022), 51 of 52 patients enrolled in the Phase 2 expansion phase of the trial had received at least one dose of tulmimetostat in the following cohorts: metastatic castration-resistant prostate cancer, lymphoma, BAP1-mutated mesothelioma, ARID1A-mutated ovarian clear cell carcinoma, ARID1A-mutated endometrial carcinoma and ARID1A-mutated urothelial and other ...
(NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. ...
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid ...
” A pre-clinical-stage company, PanTher Therapeutics is working to revolutionize the treatment of inoperable, locally advanced solid tumors − studying the direct delivery of existing, already proven chemotherapy agents directly onto the tumor for consistent, slow release over time. ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started ...
By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. ...
Although pancreatic cancer treatment has improved, pancreatic cancer patients continue to have poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered chemotherapy drug access to the cancer cells. Unlike intravenous (systemic) chemotherapy, RenovoRx’s technology delivers chemotherapy directly to the pancreas via an artery ...
ByxCures
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted in ...
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell ...